Practice GuidelinesACR Practice Parameter for the Performance of Therapy With Unsealed Radiopharmaceutical SourcesSpratt, Daniel E. MD; Zaki, Bassem I. MD; Franc, Benjamin L. MD, MS, CPE; Hartford, Alan C. MD, PhD, FACR; Osborne, Joseph R. MD, PhDAuthor Information From the *Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI; † Department of Radiation Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, NH; ‡Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA; §Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY. Received for publication July 23, 2015; revision accepted July 24, 2015. Conflicts of interest and sources of funding: none declared. Correspondence to: Joseph R. Osborne, MD, PhD, Molecular Imaging and Teraphy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howars 214a, New York, NY 10065. E-mail: firstname.lastname@example.org. Practice parameters and technical standards are published annually with an effective date of October 1 in the year in which amended, revised, or approved by the ACR Council. For practice parameters and technical standards published before 1999, the effective date was January 1 following the year in which the practice parameter or technical standard was amended, revised, or approved by the ACR Council. Development chronology for this practice parameter: 1996 (Resolution 11), Revised 2000 (Resolution 27), Revised 2005 (Resolution 21), Amended 2006 (Resolution 35), Revised 2010 (Resolution 26), Amended 2014 (Resolution 39), Revised 2015 (Resolution). Clinical Nuclear Medicine: February 2016 - Volume 41 - Issue 2 - p 106-117 doi: 10.1097/RLU.0000000000001036 Buy Metrics Abstract This practice parameter is intended to guide appropriately trained and licensed physicians performing therapy with unsealed radiopharmaceutical sources. Such therapy requires close cooperation and communication between the physicians who are responsible for the clinical management of the patient and those who administer radiopharmaceutical therapy and manage the attendant side effects. Adherence to this practice parameter should help to maximize the efficacious use of these procedures, maintain safe conditions, and ensure compliance with applicable regulations. The goal of therapy with unsealed radiopharmaceutical sources is to provide either cure or effective palliation of disease while minimizing untoward side effects and complications Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.